Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.

Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D.

BMC Cancer. 2016 Feb 22;16:135. doi: 10.1186/s12885-016-2084-9.

2.

SEOM clinical guidelines in Hereditary Breast and ovarian cancer.

Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, Teulé A, Lastra E, Brunet J, Balmaña J, Graña B; SEOM Hereditary Cancer Working Group.

Clin Transl Oncol. 2015 Dec;17(12):956-61. doi: 10.1007/s12094-015-1435-3. Epub 2015 Dec 15.

3.

Clinical guideline seom: hereditary colorectal cancer.

Guillén-Ponce C, Serrano R, Sánchez-Heras AB, Teulé A, Chirivella I, Martín T, Martínez E, Morales R, Robles L.

Clin Transl Oncol. 2015 Dec;17(12):962-71. doi: 10.1007/s12094-015-1439-z. Epub 2015 Nov 19.

4.

Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.

Murria R, Palanca S, de Juan I, Alenda C, Egoavil C, Seguí FJ, García-Casado Z, Juan MJ, Sánchez AB, Segura Á, Santaballa A, Chirivella I, Llop M, Pérez G, Barragán E, Salas D, Bolufer P.

Am J Cancer Res. 2015 Jun 15;5(7):2330-43. eCollection 2015.

5.

Mammographic density and breast cancer in women from high risk families.

Ramón Y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J, Sánchez-Heras AB, Llort G, Fisas D, Lope V, Hernández-Agudo E, Juan-Fita MJ, Tena I, Robles L, Guillén-Ponce C, Pérez-Segura P, Luque-Molina MS, Hernando-Polo S, Salinas M, Brunet J, Salas-Trejo MD, Barnadas A, Pollán M.

Breast Cancer Res. 2015 Jul 11;17:93. doi: 10.1186/s13058-015-0604-1.

6.

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.

Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z.

PMID:
26026974
7.

Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer.

Murria R, Palanca S, de Juan I, Egoavil C, Alenda C, García-Casado Z, Juan MJ, Sánchez AB, Santaballa A, Chirivella I, Segura Á, Hervás D, Llop M, Barragán E, Bolufer P.

Am J Cancer Res. 2014 Dec 15;5(1):375-85. eCollection 2015.

8.

Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.

Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, Teulé A, Fachal L, Martínez B, González-Sarmiento R, Cruz-Hernández JJ, Chirivella I, Garcés V, Garre P, Romero A, Caldés T, Díaz-Rubio E, de la Hoya M.

Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.

PMID:
25342642
9.

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.

Castellano D, Puente J, de Velasco G, Chirivella I, López-Criado P, Mohedano N, Fernández O, García-Carbonero I, González MB, Grande E.

BMC Cancer. 2014 Oct 24;14:779. doi: 10.1186/1471-2407-14-779.

10.

Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.

Martínez MT, González I, Tarazona N, Roselló S, Saiz R, Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, Franco J, Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro J, Teruel A, Lluch A, Chirivella I.

Clin Transl Oncol. 2015 Feb;17(2):167-72. doi: 10.1007/s12094-014-1209-3. Epub 2014 Aug 7.

PMID:
25100066
11.

Prevalence of germline MUTYH mutations among Lynch-like syndrome patients.

Castillejo A, Vargas G, Castillejo MI, Navarro M, Barberá VM, González S, Hernández-Illán E, Brunet J, Ramón y Cajal T, Balmaña J, Oltra S, Iglesias S, Velasco A, Solanes A, Campos O, Sánchez Heras AB, Gallego J, Carrasco E, González Juan D, Segura A, Chirivella I, Juan MJ, Tena I, Lázaro C, Blanco I, Pineda M, Capellá G, Soto JL.

Eur J Cancer. 2014 Sep;50(13):2241-50. doi: 10.1016/j.ejca.2014.05.022. Epub 2014 Jun 18.

PMID:
24953332
12.

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.

Pérez-Fidalgo JA, Bermejo B, Chirivella I, Martínez MT, González I, Cejalvo JM, Catoira I, Martínez P, Contel E, Lluch A.

Clin Transl Oncol. 2014 Sep;16(9):814-22. doi: 10.1007/s12094-013-1153-7. Epub 2014 Feb 15.

13.

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).

Andrés R, Pajares I, Balmaña J, Llort G, Ramón Y Cajal T, Chirivella I, Aguirre E, Robles L, Lastra E, Pérez-Segura P, Bosch N, Yagüe C, Lerma E, Godino J, Miramar MD, Moros M, Astier P, Saez B, Vidal MJ, Arcusa A, Ramón y Cajal S, Calvo MT, Tres A.

Clin Transl Oncol. 2014 Mar;16(3):280-4. doi: 10.1007/s12094-013-1070-9. Epub 2013 Aug 27.

PMID:
23982851
14.

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP.

Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25.

15.

The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families.

Palanca S, de Juan I, Perez-Simó G, Barragán E, Chirivella I, Martínez E, Fuster O, Bolufer P.

Fam Cancer. 2013 Mar;12(1):119-23. doi: 10.1007/s10689-012-9579-6.

PMID:
23117300
16.

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment.

Carles J, Chirivella I, Climent MA, Gallardo E, González del Alba A, Maroto JP, Mellado B, García del Muro FX.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S3-9. doi: 10.1007/s10555-012-9353-0. Review.

PMID:
22689342
17.

Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer.

Blanco A, de la Hoya M, Balmaña J, Ramón y Cajal T, Teulé A, Miramar MD, Esteban E, Infante M, Benítez J, Torres A, Tejada MI, Brunet J, Graña B, Balbín M, Pérez-Segura P, Osorio A, Velasco EA, Chirivella I, Calvo MT, Feliubadaló L, Lasa A, Díez O, Carracedo A, Caldés T, Vega A.

Breast Cancer Res Treat. 2012 Feb;132(1):307-15. doi: 10.1007/s10549-011-1842-2. Epub 2011 Nov 4.

18.

Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

Pérez-Fidalgo JA, Pimentel P, Caballero A, Bermejo B, Barrera JA, Burgues O, Martinez-Ruiz F, Chirivella I, Bosch A, Martínez-Agulló A, Lluch A.

Breast. 2011 Dec;20(6):548-54. doi: 10.1016/j.breast.2011.06.005. Epub 2011 Aug 3.

PMID:
21816613
19.

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.

Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.

20.

Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories.

Blancas I, Gómez FJ, Bermejo B, Hennessy BT, Chirivella I, Magro A, Caballero A, Ferrer J, Valero V, Lluch A.

Clin Breast Cancer. 2009 Nov;9(4):231-6. doi: 10.3816/CBC.2009.n.039.

PMID:
19933078
21.

Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.

Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, Chirivella I, Guzman C, Lluch A.

Breast Cancer Res Treat. 2010 Feb;120(1):245-51. doi: 10.1007/s10549-009-0426-x. Epub 2009 Jul 3.

PMID:
19575291
22.

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J.

Breast Cancer Res Treat. 2010 Jan;119(1):221-32. doi: 10.1007/s10549-009-0394-1. Epub 2009 Apr 16.

23.

Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain).

Pérez-Fidalgo JA, Miranda J, Chirivella I, Ibáñez J, Bermejo B, Pons C, Melchor I, Santaballa A, Martínez-Ruiz F, Lluch A, Salas D.

Clin Transl Oncol. 2008 Nov;10(11):745-52.

PMID:
19015071
24.

[Coexistence of two germinal cell tumors, seminomatous and nonseminomatous, with an uncommon clinical presentation].

Soriano Sarrió P, Chirivella I, Navarro Fos S.

Arch Esp Urol. 2008 Jun;61(5):626-30. Spanish.

PMID:
18709819
25.

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.

Martín-Martorell P, Roselló S, Rodríguez-Braun E, Chirivella I, Bosch A, Cervantes A.

Br J Cancer. 2008 Aug 5;99(3):455-8. doi: 10.1038/sj.bjc.6604530.

26.

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.

Chirivella I, Bermejo B, Insa A, Pérez-Fidalgo A, Magro A, Rosello S, García-Garre E, Martín P, Bosch A, Lluch A.

Breast Cancer Res Treat. 2009 Apr;114(3):479-84. doi: 10.1007/s10549-008-0018-1. Epub 2008 May 8.

PMID:
18463977
27.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.

28.

Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, Tournigand C.

J Clin Oncol. 2007 Aug 1;25(22):3224-9.

PMID:
17664470
29.

Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women.

Martinez-Ferrandis JI, Rodríguez-López R, Milne RL, González E, Cebolla E, Chirivella I, Zamora P, Arias JI, Palacios S, Cervantes A, Díez O, Benitez J, Armengod ME.

Cancer Biomark. 2007;3(2):89-93.

PMID:
17522430
30.

Parotid gland metastasis of a breast cancer.

Perez-Fidalgo JA, Chirivella I, Laforga J, Colio JM, Blanes MD, Baydal R, Roselló S, De-la-Morena E, Lluch A.

Clin Transl Oncol. 2007 Apr;9(4):264-5.

PMID:
17462982
31.

A multimodality approach to localized rectal cancer.

Cervantes A, Chirivella I, Rodriguez-Braun E, Campos S, Navarro S, García Granero E.

Ann Oncol. 2006 Sep;17 Suppl 10:x129-34. Review. No abstract available.

PMID:
17018713
32.

[Neoadjuvant therapy for operable breast-cancer].

Insa A, Chirivella I, Lluch A.

Med Clin (Barc). 2006 Mar 4;126(8):295-303. Review. Spanish.

PMID:
16527157
33.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A.

J Clin Oncol. 2006 Jan 20;24(3):394-400.

PMID:
16421419
34.

Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.

Maurel J, Cervantes A, Conill C, Salazar R, Martin-Richard M, Pera M, Manzano H, Chirivella I, Gallego R, Marfa X.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):91-6.

PMID:
15850907
35.

Oncological emergencies.

Cervantes A, Chirivella I.

Ann Oncol. 2004;15 Suppl 4:iv299-306. Review. No abstract available.

PMID:
15477325
36.

Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.

Martínez-Ferrandis JI, Vega A, Chirivella I, Marín-García P, Insa A, Lluch A, Carracedo A, Chaves FJ, García-Conde J, Cervantes A, Armengod ME.

Hum Mutat. 2003 Nov;22(5):417-8.

PMID:
14517958

Supplemental Content

Loading ...
Support Center